Chimeric Therapeutics (ASX:CHM) has moved to reassure investors of its strategic direction and clinical momentum, announcing a forthcoming refresh of its board and reaffirmed backing from major shareholders following its Annual General Meeting held on 25 November. …
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 Australian Biotech
Latest Video
New Stories
-
Chimeric signals board refresh and shareholder support as lead trial advances
November 30, 2025 - - Australian Biotech -
Pharmac announces 90-day dispensed quantities of HIV medicines
November 27, 2025 - - Latest News -
Landmark report warns Australia’s hospital pharmacy system is at an 'inflection point'
November 27, 2025 - - Latest News -
Australia releases first national estimate of women living with metastatic breast cancer
November 27, 2025 - - Latest News -
Imugene and JW Therapeutics join forces on first-in-class combination for solid tumours
November 27, 2025 - - Australian Biotech -
Algorae Pharmaceuticals secures new supply of chemotherapy for Australia through Dr Reddy’s partnership
November 27, 2025 - - Latest News -
An interview that reminds us of the missing discussion in Australia
November 27, 2025 - - Latest News